Based on growing evidence showing a better prognosis in individuals with lower levels of low-density lipoprotein cholesterol (LDL-C), updated 2019 European Society of Cardiology guidelines have further reduced LDL-C targets in patients with higher cardiovascular risk. National and international observational clinical studies demonstrated a significant gap between goals recommended by international guidelines and LDL-C levels achieved in the real world, especially in patient populations at higher risk. Combination treatment strategies with more lipid-lowering drugs represent effective and safe options for the achievement of recommended targets. The introduction of new drugs, such as bempedoic acid, further expands the available therapeutic armamentarium for hypercholesterolemia management.
|Translated title of the contribution||Dyslipidemias: New therapeutic targets and relevance of combination therapies|
|Journal||Giornale Italiano di Cardiologia|
|Publication status||Published - Apr 2021|
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine